A robust mRNA signature obtained via recursive ensemble feature selection predicts the responsiveness of omalizumab in moderate‐to‐severe asthma

BACKGROUND: Not being well controlled by therapy with inhaled corticosteroids and long‐acting β2 agonist bronchodilators is a major concern for severe‐asthma patients. The current treatment option for these patients is the use of biologicals such as anti‐IgE treatment, omalizumab, as an add‐on thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Kidwai, Sarah, Barbiero, Pietro, Meijerman, Irma, Tonda, Alberto, Perez‐Pardo, Paula, Lio ´, Pietro, van der Maitland‐Zee, Anke H., Oberski, Daniel L., Kraneveld, Aletta D., Lopez‐Rincon, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655633/
https://www.ncbi.nlm.nih.gov/pubmed/38006387
http://dx.doi.org/10.1002/clt2.12306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655633/
https://www.ncbi.nlm.nih.gov/pubmed/38006387
http://dx.doi.org/10.1002/clt2.12306

Ejemplares similares